Hyloris Pharmaceuticals (HYL) H2 2025 earnings summary

Executive summary

• Royalty income grew 15% year-over-year to €5.6 million, led by a 98% increase in MaxigesicⓇ IV and Sotalol IV royalties, despite temporary Podofilox Gel stock-out and adverse currency effects.

• Combined recurring revenues (royalties and product sales) rose to €5.9 million from €4.9 million in 2024, with first product sales from Tranexamic RTU.

• Total operating income declined 12% year-over-year to €8.8 million, mainly due to lower non-recurring milestone revenue and currency headwinds.

• Six new products added, expanding the portfolio to over 30 assets; eight new out-licensing agreements and partnerships signed internationally.

• Net loss remained stable at €6.3 million, reflecting disciplined cost management amid continued R&D investment.

Financial highlights

• Royalties: €5.6 million (+15% YoY); Milestones: €1.4 million (-62% YoY, adjusted -14% YoY); Product sales: €0.2 million (first contribution).

• Revenue: €7.2 million (-15% YoY); Operating income: €8.8 million (-12% YoY); Operating expenses: €15.6 million (-9% YoY).

• Operating loss (EBIT): €6.8 million (improved 5% YoY); Net loss: €6.3 million (flat YoY).

• Cash and cash equivalents: €13.8 million (down 42% YoY); Equity: €26.5 million (down 18% YoY); No financial debt.

Outlook and guidance

• Continued advancement of the development portfolio and pursuit of additional strategic growth opportunities supported by strong cash position.

• U.S. commercial promotion for MaxigesicⓇ IV expected to intensify from late Q2 2026; China partner discussions ongoing.

• Multiple regulatory submissions and clinical trial completions expected in 2026, including Dofetilide IV and Atomoxetine Oral Liquid.